
ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Adelba Torres, Hospital Auxilio Mutuo, San Juan, PR.
We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the efficacy and safety of bispecific antibodies in an ethnically and racially diverse patient population?
In this interview, Torres highlights how the findings from the EPCORE NHL-6 trial support the safe and efficacious administration of subcutaneous epcoritamab in the outpatient setting in adult…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.